Study to evaluate the clinical effectiveness of intermittent infusion hemodiafiltration (I-HDF)

Study to evaluate the clinical effectiveness of intermittent infusion hemodiafiltration (I-HDF) - Study to evaluate the clinical effectiveness of I-HDF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015891

Enrollment

Registered

2014-12-10

Start date

2014-09-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Failure

Interventions

HD therapy (for 3 months) --&gt

I-HDF therapy (for 3 months) --&gt

HD therapy (for 3 months) I-HDF therapy (for 3 months) --&gt

I-HDF therapy (for 3 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patient who on-line HDF therapy is possible, and can give written informed consent - 18 years and over - Hemodialysis for more than 6 months

Exclusion criteria

Exclusion criteria: 1) Patients with severe cardiovascular disease (NYHA class 3 or 4), hepatic failure, respiratory failure, or malignant tumor 2) 8% or more of the rate of weight gain 3) Patients who are judged ineligible by the attending physician.

Design outcomes

Primary

Measure	Time frame
SF-36 ver2 Clinical condition (VAS scale)	—

Secondary

Measure	Time frame
Vital signs (blood pressure, pulse) Number of treatments by medical staff Blood test Dose of erythropoietin-stimulating agent Solute removal ability	—

Countries

Japan

Contacts

Public ContactRyoichi Sakiyama

Tokyo Women's Medical University Department of Clinical Engineering

sakiyama@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026